Anthem (ANTX) Competitors

$4.46 0.00 (0.00%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$4.46 0.00 (0.00%)

As of 09:01 AM Eastern

ANTX vs. ELYM, SBTX, LWAC, NLTX, and WHWK

Should you be buying Anthem stock or one of its competitors? The main competitors of Anthem include Eliem Therapeutics (ELYM), Silverback Therapeutics (SBTX), LightWave Acquisition (LWAC), Neoleukin Therapeutics (NLTX), and Whitehawk Therapeutics (WHWK).

How does Anthem compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Anthem had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Anthem	Neutral

Eliem Therapeutics' return on equity of -47.03% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Anthem	N/A	-55.04%	-49.13%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 20.8% of Anthem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A

Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500.

Summary

Eliem Therapeutics and Anthem tied by winning 5 of the 10 factors compared between the two stocks.

How does Anthem compare to Silverback Therapeutics?

Anthem (NASDAQ:ANTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Anthem had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Silverback Therapeutics. Anthem's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Anthem	Neutral
Silverback Therapeutics	Neutral

Silverback Therapeutics' return on equity of -29.62% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-55.04%	-49.13%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Anthem has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

90.5% of Anthem shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 20.8% of Anthem shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anthem is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Anthem and Silverback Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Anthem compare to LightWave Acquisition?

LightWave Acquisition (NASDAQ:LWAC) and Anthem (NASDAQ:ANTX) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

90.5% of Anthem shares are owned by institutional investors. 20.8% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LightWave Acquisition's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Anthem	N/A	-55.04%	-49.13%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Anthem had 3 more articles in the media than LightWave Acquisition. MarketBeat recorded 3 mentions for Anthem and 0 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.

Company	Overall Sentiment
LightWave Acquisition	Neutral
Anthem	Neutral

Summary

Anthem beats LightWave Acquisition on 3 of the 5 factors compared between the two stocks.

How does Anthem compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 20.8% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neoleukin Therapeutics' return on equity of -37.22% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Anthem	N/A	-55.04%	-49.13%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Anthem has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500.

In the previous week, Anthem had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Anthem'saverage media sentiment score.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Anthem	Neutral

Summary

Anthem beats Neoleukin Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Anthem compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Anthem (NASDAQ:ANTX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Anthem. MarketBeat recorded 4 mentions for Whitehawk Therapeutics and 3 mentions for Anthem. Whitehawk Therapeutics' average media sentiment score of 1.09 beat Anthem's score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics currently has a consensus target price of $7.33, suggesting a potential upside of 84.72%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Whitehawk Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anthem	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Whitehawk Therapeutics has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	27.50	-$20.60M	-$1.68	N/A
Anthem	N/A	N/A	-$35.17M	-$1.16	N/A

Anthem's return on equity of -55.04% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-74.63%	-69.67%
Anthem	N/A	-55.04%	-49.13%

Whitehawk Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 20.8% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Whitehawk Therapeutics beats Anthem on 10 of the 14 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$160.56M	$947.72M	$6.23B	$12.31B
Dividend Yield	N/A	4.84%	2.78%	5.22%
P/E Ratio	-3.84	1.56	20.97	25.41
Price / Sales	N/A	123.00	558.82	76.67
Price / Cash	N/A	20.07	27.81	36.27
Price / Book	2.30	7.61	9.81	6.80
Net Income	-$35.17M	-$3.57M	$3.55B	$333.85M
7 Day Performance	N/A	N/A	N/A	0.39%
1 Month Performance	50.17%	50.87%	7.06%	9.67%
1 Year Performance	271.67%	104.27%	42.06%	41.51%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	0.1872 of 5 stars	$4.46 flat	N/A	+271.7%	$160.56M	N/A	N/A	N/A	Gap Up
ELYM Eliem Therapeutics	N/A	$12.22 +6.7%	N/A	+855.5%	$363.57M	N/A	N/A	9	High Trading Volume
SBTX Silverback Therapeutics	N/A	$9.28 +2.8%	N/A	-35.0%	$334.62M	N/A	N/A	83	High Trading Volume
LWAC LightWave Acquisition	N/A	$10.18 +0.0%	N/A	N/A	$306.06M	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	$28.94 +2.6%	N/A	+109.0%	$271.98M	N/A	N/A	90	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. ELYM, SBTX, LWAC, NLTX, and WHWK

How does Anthem compare to Eliem Therapeutics?

Summary

How does Anthem compare to Silverback Therapeutics?

Summary

How does Anthem compare to LightWave Acquisition?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Summary

How does Anthem compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. ELYM, SBTX, LWAC, NLTX, and WHWK

How does Anthem compare to Eliem Therapeutics?

Does the media refer more to ELYM or ANTX?

Is ELYM or ANTX more profitable?

Do analysts recommend ELYM or ANTX?

Do insiders and institutionals believe in ELYM or ANTX?

Which has stronger valuation and earnings, ELYM or ANTX?

Which has more volatility & risk, ELYM or ANTX?

Summary

How does Anthem compare to Silverback Therapeutics?

Does the media prefer ANTX or SBTX?

Is ANTX or SBTX more profitable?

Do analysts recommend ANTX or SBTX?

Which has more risk & volatility, ANTX or SBTX?

Do institutionals and insiders believe in ANTX or SBTX?

Which has preferable valuation & earnings, ANTX or SBTX?

Summary

How does Anthem compare to LightWave Acquisition?

Do institutionals & insiders have more ownership in LWAC or ANTX?

Is LWAC or ANTX more profitable?

Which has stronger earnings & valuation, LWAC or ANTX?

Do analysts rate LWAC or ANTX?

Does the media refer more to LWAC or ANTX?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Do institutionals & insiders have more ownership in NLTX or ANTX?

Is NLTX or ANTX more profitable?

Which has stronger earnings & valuation, NLTX or ANTX?

Do analysts rate NLTX or ANTX?

Which has more volatility and risk, NLTX or ANTX?

Does the media favor NLTX or ANTX?

Summary

How does Anthem compare to Whitehawk Therapeutics?

Does the media refer more to WHWK or ANTX?

Do analysts recommend WHWK or ANTX?

Which has higher valuation and earnings, WHWK or ANTX?

Is WHWK or ANTX more profitable?

Which has more risk and volatility, WHWK or ANTX?

Do insiders and institutionals have more ownership in WHWK or ANTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools